Document 2812
 DOCN  M94A2812
 TI    Use of DNCB as a immune modulator in HIV positive patients--a pilot
       study.
 DT    9412
 AU    Traub A; Irmandade da Santa Casa de Misericordia de Porto Alegre,
       Brazil.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):219 (abstract no. PB0304). Unique
       Identifier : AIDSLINE ICA10/94369763
 AB    OBJECTIVE: To evaluate the efficacy of topical DNCB application in
       patients with early HIV disease. METHODS: This study was performed in a
       public hospital where patients are routinely seen free of charge.
       Patients of both genders were included in the sample. All forms of
       transmissions were included as well. Inclusion criteria were (1) HIV
       seropositivity with CD4 T cells counts between 100 and 600
       cells/microliters, (2) no previous use of DNCB either no current use of
       antiretroviral therapy. Application of DNCB was initiated with a 2%
       acetone solution. If no sensitization were accomplished, a DNCB in a 10%
       solution was applied, repeated weekly until a positive response were
       obtained. After that maintenance weekly application of a 2% or 1% DNCB
       solution was applied. Usually the solution was applied to a 3.0 cm2 in
       the forearm. Until the present were followed 14 patients, 8 men and 6
       women for a average period of 10 months. Clinical evaluation were
       performed every three weeks. Peripheral blood lymphocytes subsets were
       analyzed each 6 weeks, using monoclonal antibodies and flow cytometry,
       including helper/inducer T cells (CD4) and suppressor/cytotoxic T cells
       (CD8). RESULTS: (1) None of the patients developed opportunistic
       infection or malignancy. (2) All patients have gain weight. (3) CD4
       counts remained stable or had a slight increase. (3) CD8 counts had a
       significant increase. No side effects other than mild eczema were found.
       CONCLUSION: Considering the low cost, the convenience of the easy
       application and the good results found until the present date, we
       suggest that this drug can be useful for the treatment of HIV early
       infection. We acknowledge that comparative studies must be done to prove
       the real efficacy of the DNCB use.
 DE    Adjuvants, Immunologic/ADMINISTRATION & DOSAGE/PHARMACOLOGY/
       *THERAPEUTIC USE  Administration, Cutaneous
       Dinitrochlorobenzene/ADMINISTRATION & DOSAGE/PHARMACOLOGY/  *THERAPEUTIC
       USE  Drug Evaluation  Female  Human  HIV Infections/*THERAPY  Immunity,
       Cellular/DRUG EFFECTS  Male  Treatment Outcome  Weight Gain/DRUG EFFECTS
       MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).